Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NeoRecormon epoetin beta regulatory update

Amgen Inc. (AMGN, Thousand Oaks, Calif.) said EMEA's CHMP proposed to amend the EU prescribing information for erythropoiesis-stimulating

Read the full 197 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE